- Home
- PLRX vs HYPD Comparison
PLRX vs HYPD Comparison
Compare PLRX & HYPD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PLRX
- HYPD
- Stock Information
- Founded
- PLRX 2015
- HYPD 2014
- Country
- PLRX United States
- HYPD United States
- Employees
- PLRX N/A
- HYPD N/A
- Industry
- PLRX Biotechnology: Pharmaceutical Preparations
- HYPD
- Sector
- PLRX Health Care
- HYPD
- Exchange
- PLRX Nasdaq
- HYPD NYSE
- Market Cap
- PLRX 77.3M
- HYPD 73.3M
- IPO Year
- PLRX 2020
- HYPD 2018
- Fundamental
- Price
- PLRX $1.40
- HYPD $12.52
- Analyst Decision
- PLRX Hold
- HYPD
- Analyst Count
- PLRX 10
- HYPD 0
- Target Price
- PLRX $9.79
- HYPD N/A
- AVG Volume (30 Days)
- PLRX 1.6M
- HYPD 6.5M
- Earning Date
- PLRX 08-06-2025
- HYPD 08-11-2025
- Dividend Yield
- PLRX N/A
- HYPD N/A
- EPS Growth
- PLRX N/A
- HYPD N/A
- EPS
- PLRX N/A
- HYPD N/A
- Revenue
- PLRX N/A
- HYPD $67,063.00
- Revenue This Year
- PLRX N/A
- HYPD N/A
- Revenue Next Year
- PLRX N/A
- HYPD N/A
- P/E Ratio
- PLRX N/A
- HYPD N/A
- Revenue Growth
- PLRX N/A
- HYPD 663.82
- 52 Week Low
- PLRX $1.10
- HYPD $0.85
- 52 Week High
- PLRX $16.10
- HYPD $124.80
- Technical
- Relative Strength Index (RSI)
- PLRX 54.68
- HYPD N/A
- Support Level
- PLRX $1.13
- HYPD N/A
- Resistance Level
- PLRX $1.27
- HYPD N/A
- Average True Range (ATR)
- PLRX 0.11
- HYPD 0.00
- MACD
- PLRX 0.02
- HYPD 0.00
- Stochastic Oscillator
- PLRX 90.00
- HYPD 0.00
About PLRX Pliant Therapeutics Inc.
Pliant Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis and related diseases. Its primary product candidate is bexotegrast (PLN-74809), an oral, small molecule, that the company is developing for the treatment of idiopathic pulmonary fibrosis, or IPF, and primary sclerosing cholangitis.
About HYPD HYPERION DEFI INC
Hyperion DeFi Inc is a clinical-stage ophthalmic company developing a pipeline of therapeutics based on its proprietary array print (MAP) platform technology. It aims to achieve clinical microdosing of next-generation formulations of novel and existing ophthalmic pharmaceutical agents using its high-precision targeted ocular delivery system, branded the Optejet, which has the potential to replace conventional eye dropper delivery and improve safety, tolerability, patient compliance, and topical delivery success for ophthalmic eye treatments. Using its proprietary delivery technology, Eyenovia is developing the next generation of smart ophthalmic therapies that target new indications or new combinations.